Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.
Official title: Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Run by Ruijin Hospital · NCT07198165 · Data updated 2026-11-12
This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 104 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, bevacizumab |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | September 5, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT07198165 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with previously untreated locally advanced rectal adenocarcinoma meeting specified MRI risk features, ECOG 0–1, adequate organ function, and no BRAF mutation or MSI‑high status are ideal candidates.
✕Probably not a fit
Patients with BRAF mutations, MSI‑high tumors, distant metastases, severe intestinal obstruction, poor performance status, or inadequate organ function are unlikely to be eligible or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 trial gives patients short-course radiotherapy (SCRT) and then systemic chemotherapy with CAPOX plus bevacizumab, with randomization or assignment to receive a PD‑1 inhibitor or not as part of total neoadjuvant therapy. Eligible patients are adults with untreated locally advanced rectal adenocarcinoma defined by MRI criteria (T3c‑T4, N2, EMVI+, MRF+, or low‑lying tumors not suitable for sphincter preservation) and adequate organ function. Patients with BRAF mutations or MSI‑high tumors are excluded, and standard imaging is used to rule out distant metastases before enrollment. Primary goals include improving complete response and local control while monitoring safety and distant metastasis rates.
Why it matters
Potential benefit: If successful, adding PD‑1 immunotherapy could raise complete response rates and reduce distant spread, possibly increasing organ preservation and improving long‑term outcomes.
How similar studies have gone: PD‑1 inhibitors have clear efficacy in MSI‑high colorectal cancer, but combining immunotherapy with chemoradiation in microsatellite‑stable locally advanced rectal cancer is a newer approach with limited early‑phase data showing mixed but encouraging signals.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy. * Exclusion of patients with BRAF mutations or MSI-H status, as determined by pre-enrollment genetic testing including RAS, BRAF, and MSI analysis. RAS mutation status is permitted regardless. * Absence of severe intestinal obstruction symptoms and no evidence of distant metastasis confirmed by imaging examinations such as CT, MRI, or PET/CT. * Confirmation as locally advanced rectal cancer by rectal MRI, meeting one or more of the following criteria: T3c-d or T4, N2, EMVI(+), MRF(+), lateral lymph node metastasis; or patients with low-lying rectal cancer (≤5 cm from the anal verge) unsuitable for sphincter-preserving surgery prior to neoadjuvant therapy. * Age 18 to 75 years. * ECOG Performance Status of 0 to 1, without severe comorbid medical conditions. * Adequate organ function: Hematopoietic: Hemoglobin ≥90 g/L, Platelets ≥80 × 10\^9/L, Absolute Neutrophil Count ≥1.5 × 10\^9/L. Hepatic: ALT and AST \< 2.5 × ULN. Renal: Serum Creatinine \< 1.5 × ULN. * Provision of signed and dated written informed consent. Exclusion Criteria: * Patients found to have BRAF mutations or MSI-H status. * Patients who have previously received chemotherapy, radiotherapy, immunotherapy, targeted therapy, or surgical resection for colorectal cancer prior to enrollment. * History or presence of another malignancy (except for early-stage basal cell carcinoma or carcinoma in situ of the cervix) within the past 3 years, with the disease not under control. * Patients who are pregnant (confirmed by serum or urine β-HCG test) or breastfeeding. * Patients with severe cardiac, hepatic, renal, neurological, or psychiatric diseases. * Patients with active infections. * Poor overall health status, with an ECOG performance status ≥2. * Patients who have undergone organ transplantation requiring immunosuppressive therapy, or those requiring long-term corticosteroid treatment for autoimmune diseases. * Patients with comorbid conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the completion of the study. * Known hypersensitivity to any of the study drugs.
Where it's running
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China Recruiting
Study contacts
- Study coordinator: Bo Feng
- Email: Fengbo2022@163.com
- Phone: +86 21 64370045
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-course versus short-course radiotherapy before immunotherapy and total neoadjuvant therapy for locally advanced rectal cancer
This trial tests whether adding immunotherapy to total neoadjuvant therapy and using short-course versus long-course radiotherapy improves outcomes for adults with locally advanced rectal cancer.
-
Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments
This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.
-
Comparing total neoadjuvant therapy with surgery for rectal cancer treatment
This study is testing if rectal cancer patients who respond well to a new treatment can skip surgery and just be monitored to see how they do compared to those who have surgery right away.
-
Short-course radiotherapy followed by PD-1 inhibitor and FOLFOX vs standard chemoradiotherapy for high‑risk locally advanced lower rectal cancer
This trial tests whether giving a short course of radiotherapy followed by a PD-1 inhibitor and FOLFOX can be better than the usual long-course chemoradiotherapy for adults with high‑risk, locally advanced, pMMR/MSS lower rectal cancer.
-
Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer
This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.
-
Emotional health and outcomes for advanced liver cancer patients receiving HAIC plus targeted therapy and immunotherapy
We will see if baseline emotional status (depressive versus non‑depressive) changes treatment outcomes in adults with BCLC stage B/C hepatocellular carcinoma getting hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.